Cochlear Limited (ASX:COH): Why FY26 Profit Fell Despite Higher Revenue

Aditi Sarkar

04 November 2026 07:58 PM AEDT

Cochlear Limited (ASX:COH): Why FY26 Profit Fell Despite Higher Revenue

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue reached AUD 2,343.4 million, up 2% on a constant-currency basis.
Underlying net profit after tax fell 22% YoY to AUD 322.4 million.
Gross Margin declined to 71% from 74% in the comparative period.
Operating cash flow reached AUD 368 million, an increase of AUD 130 million.
FY27 underlying net profit after tax guidance is AUD 330–350 million.

Cochlear Limited (ASX:COH) develops and supplies implantable hearing technologies and related services. Its FY26 results showed that modest revenue growth did not translate into higher underlying earnings. Revenue reached AUD 2,343.4 million, rising 2% on a constant-currency basis, while underlying net profit after tax declined 22% YoY to AUD 322.4 million. The gap between sales and profit makes gross margin, Investment spending and product adoption important measures for the year ahead.

Revenue, margins and underlying earnings

Cochlear Limited (ASX:COH) reported a FY26 gross margin of 71%, compared with 74% in the preceding year. The three-percentage-point decline indicates that the cost of generating revenue absorbed a greater share of sales. Margin movements can reflect product mix, Manufacturing and supply-chain factors, although the figures alone do not establish how much each Factor contributed.

Underlying net profit after tax was AUD 322.4 million, down 22% YoY, despite revenue rising in constant-currency terms. Constant-currency growth removes the effect of exchange-rate movements from the comparison; it is not the same as reported Australian-dollar revenue growth. These distinctions are material for a global medical-device company selling into multiple currencies.

Implant portfolio and customer adoption

The Nucleus Nexa implant featured prominently in Cochlear Limited's (ASX:COH) FY26 product transition. The company reported that Nexa represented more than 95% of implant sales in developed markets. This adoption rate describes the mix of implant sales in those markets, not the proportion of all hearing devices sold globally.

Product transitions can support longer-term positioning but may also involve training, launch costs and inventory changes. The commercial question is whether sustained adoption produces growth in implant volumes, services and profitability. Cochlear's activities span implant systems and associated support, meaning performance is affected by access to treatment, clinical pathways and reimbursement arrangements as well as product specifications.

Cash flow, dividends and FY27 investment

Operating cash flow at Cochlear Limited (ASX:COH) reached AUD 368 million in FY26, up AUD 130 million. This improvement contrasted with the fall in underlying net profit, underscoring that accounting Earnings and cash conversion can move differently in a given period. The total FY26 Dividend was AUD 3.45 per share, down 20% from the prior year. Dividend decisions reflect board assessment and should not be treated as a guarantee of future payments.

For FY27, Cochlear guided to low-single-digit constant-currency revenue growth and underlying net profit after tax of AUD 330–350 million. The company also outlined an additional AUD 25 million of investment. Higher spending could support future product and service development while weighing on near-term margins. Delivery against guidance will depend on sales growth, cost management and the timing of investment benefits.

Key Insights

Cochlear Limited (ASX:COH) delivered higher constant-currency revenue and stronger Operating Cash Flow in FY26, but lower margins and underlying earnings. Its FY27 guidance suggests a measured profit recovery rather than a return to uninterrupted growth. Product adoption, gross margin and the effect of additional investment will be useful indicators of progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.